Evidence map›Paper›PMID 37161885›Full record

ArticleJournal of biomedical research2022

Antitumor efficacy of multi-target

Anastasia S Proskurina, Vera S Ruzanova, Genrikh S Ritter, Yaroslav R Efremov, Zakhar S Mustafin, Sergey A Lashin, Ekaterina A Burakova, Alesya A Fokina, Timofei S Zatsepin, Dmitry A Stetsenko and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Local CpG-Molecular therapy. Nucleic acids · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Anastasia S ProskurinaInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Vera S RuzanovaInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Genrikh S RitterInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Yaroslav R EfremovInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Zakhar S MustafinInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Sergey A LashinInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Ekaterina A BurakovaInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Alesya A FokinaInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Timofei S ZatsepinDepartment of Chemistry, Moscow State University, Moscow 119991, Russia.
Dmitry A StetsenkoInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Olga Y LeplinaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, 630099, Russia.
Alexandr A OstaninResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, 630099, Russia.
Elena R ChernykhResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, 630099, Russia.
Sergey S BogachevInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Institute of Cytology and Genetics · RUNovosibirsk State University · RUResearch Institute of Fundamental and Clinical Immunology · RULomonosov Moscow State University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To overcome immune tolerance to cancer, the immune system needs to be exposed to a multi-target action intervention. Here, we investigated the activating effect of CpG oligodeoxynucleotides (ODNs), mesyl phosphoramidate CpG ODNs, anti-OX40 antibodies, and OX40 RNA aptamers on major populations of immunocompetent cells

Indexed as

A20 B cell lymphomaEhrlich carcinomaimmunogenicityKrebs-2 carcinomaLewis carcinomamesyl phosphoramidate

Identifiers

PMID37161885
PMCPMC10226083
OpenAlexW4312748751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.